All News

Found 324 articles

• ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

  4/12/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, presented four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting.

• ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

  3/10/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, announced four preclinical poster presentations at the 2021 American Association for Cancer Research virtual annual meeting on April 10-15, 2021.

• Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

  3/2/2021

  Epizyme’s Next EPIsode: Vision for Rewriting Oncology Treatment with Epigenetics Showcased New Five-Year Corporate Strategy

• Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results

  2/24/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter 2020 financial results and provided a business update.

• Epizyme to Host Strategic Vision Call on March 2, 2021

  2/24/2021

  Event to Showcase Epizyme’s Five-Year Corporate Strategy, TAZVERIK® Ongoing Development Plans and Advancements in the Company’s Epigenetic Pipeline

• Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

  2/23/2021

  Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, provided business and portfolio updates and reported fourth quarter and full year 2020 financial results.

• Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

  2/19/2021

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference.

• Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results

  2/18/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on February 24, 2021, to discuss its fourth quarter 2020 results and provide a business update

• Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences

  2/16/2021

  Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results and other business highlights and will participate in two upcoming investor conferences.

• Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer

  1/7/2021

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021.

• Constellation Pharmaceuticals Presents at J.P. Morgan Healthcare Conference

  1/6/2021

  CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P. Morgan Healthcare Conference at 10:50 AM EST on Thursday, January 14, 2021. A live audio webcast of the presentation and archive for replay will be available on the Investor Relations section of Constellation’s website at  http://ir.constellationpharma.com/events-and-presentations/events . The audio webca

• Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

  12/7/2020

  Cellworks Group , Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-021-01 clinical trial, which found that the Cellworks Omics Biology Model (CBM) predicted response to Arsenic Trioxide (ATO) and All-trans-retinoic Acid (ATRA) in Acute Promyelocytic Leukemia (APL) patients harboring PML-RARA fusions with 93% accuracy.

• Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

  12/7/2020

  Cellworks Group, Inc. , a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-021-02 clinical study, which found that personalized therapy response biosimulation using the Cellworks Omics Biology Model (CBM) can improve prognostication and identify new therapeutic options for Acute Myeloid Leukemia (AML)

• Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting

  12/6/2020

  67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeks

• Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting

  11/23/2020

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a virtual analyst/investor event and conference call on December 7 at 8:00 AM EDT to discuss the data from two oral presentations and two posters on the MANIFEST clinical trial for CPI-0610 being presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

• Epizyme to Participate in Jefferies Virtual London Healthcare Conference

  11/11/2020

  Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference on Thursday, Nov. 18, 2020 at 12:35 p.m. ET. A live webcast of the fireside chat will be available in t

• Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives

  11/6/2020

  Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that the company has entered into an amended and restated agreement with funds managed by Pharmakon Advisors, LP, an affiliate of Royalty Pharma, to expand its loan facility and plans to draw down $150 million.

• Epizyme Reports Business Progress and Third Quarter 2020 Financial Results

  11/6/2020

  Expansion of Loan Facility with Pharmakon Advisors; $150 Million Drawn Down to Fund Important Growth Initiatives and Extend Operating Runway into At Least 2023

• Epizyme Announces Date of Third Quarter 2020 Financial Results

  10/30/2020

  Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that management will host a conference call and webcast to discuss its third quarter 2020 financial results and other business highlights on Friday, Nov. 6, 2020 at 8:00 a.m. ET.

• Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results

  10/29/2020

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its third-quarter 2020 financial results.